



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

Identification and characterization of a dipeptidyl peptidase IV inhibitor from aronia juice

Miyuki Kozuka^a, Takuya Yamane^{b,*}, Yoshihisa Nakano^c, Takenori Nakagaki^d,
Iwao Ohkubo^e, Hiroyoshi Ariga^b

^a Department of Health and Nutrition, Faculty of Human Science, Hokkaido Bunkyo University, Eniwa 061-1449, Japan

^b Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-ku, Sapporo 060-0812, Japan

^c Center for Research and Development Bioresources, Research Organization for University-Community Collaborations, Osaka Prefecture University, Sakai, Osaka 599-8570, Japan

^d Institute of Food Sciences, Nakagaki Consulting Engineer Co., Ltd, Nishi-ku, Sakai 593-8328, Japan

^e Department of Nutrition, School of Nursing and Nutrition, Tenshi College, Higashi-ku, Sapporo 065-0013, Japan

ARTICLE INFO

Article history:

Received 29 July 2015

Accepted 8 August 2015

Available online xxx

Keywords:

Aronia juice

DPP IV inhibitor

Cyanidin 3, 5-diglucoside

Antidiabetic effect

ABSTRACT

Aronia berries have many potential effects on health, including an antioxidant effect, effect for anti-mutagenesis, hepatoprotection and cardioprotection, an antidiabetic effect and inhibition of cancer cell proliferation. Previous human studies have shown that aronia juice may be useful for treatment of obesity disorders. In this study, we found that aronia juice has an inhibitory effect against dipeptidyl peptidase IV (DPP IV) (EC 3.4.14.5). DPP IV is a peptidase that cleaves the N-terminal region of incretins such as glucagon-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Inactivation of incretins by DPP IV induces reduction of insulin secretion. Furthermore, we identified that cyanidin 3, 5-diglucoside as the DPP IV inhibitor in aronia juice. DPP IV was inhibited more strongly by cyanidin 3, 5-diglucoside than by cyanidin and cyanidin 3-glucoside. The results suggest that DPP IV is inhibited by cyanidin 3, 5-diglucoside present in aronia juice. The antidiabetic effect of aronia juice may be mediated through DPP IV inhibition by cyanidin 3, 5-diglucoside.

© 2015 Published by Elsevier Inc.

1. Introduction

Aronia berries have various potential health effects, including an antioxidant effect by radical scavenging activity, antimutagenesis by phenolic compounds, hepatoprotection by anthocyanins, which decrease the toxicity and accumulation of cadmium, cardioprotection in men with mild hypercholesterolaemia, antidiabetic effect, and inhibition of colon cancer cell proliferation [1]. Aronia juice has been shown to have a beneficial effect on plasma glucose level in diabetic humans [2] and rats [3]. However, its mechanism is unknown.

Dipeptidyl peptidase IV (DPP IV) (EC 3.4.14.5) is a serine peptidase [4] that cleaves the N-terminal region of incretins such as

glucagon-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and reduction of insulin secretion is induced by inactivation of incretin by DPP IV [5–8]. DPP IV inhibitors have beneficial effects on plasma glucose level in diabetic patients [9]. DPP IV inhibitors have also been found in several plants [10].

In this study, we found that aronia juice has an inhibitory effect on DPP IV. Furthermore, we identified cyanidin 3, 5-diglucoside as the DPP IV inhibitor in aronia juice. DPP IV was inhibited more strongly by cyanidin 3, 5-diglucoside than by cyanidin and cyanidin 3-glucoside. The antidiabetic effect of aronia juice may be mediated through DPP IV inhibition by cyanidin 3, 5-diglucoside.

2. Materials and methods

2.1. Materials

Aronia juice was kindly provided by Nakagaki Consulting Engineer (Osaka, Japan). Gly-Pro-MCA was purchased from Peptide Institute (Osaka, Japan). DPP IV was purified from porcine seminal

Abbreviations: DPP IV, dipeptidyl peptidase IV; GIP, glucagon-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; MCA, methylcumarin amide.

* Corresponding author.

E-mail address: t-yamane@pharm.hokudai.ac.jp (T. Yamane).

<http://dx.doi.org/10.1016/j.bbrc.2015.08.031>

0006-291X/© 2015 Published by Elsevier Inc.

plasma [4]. Supel Sphere Carbon/NH₂ SPE Cartridge, InertSustain C18 column and ACQUITY UPLC M-Class HSS T3 column were obtained from SUPELCO (PA, USA), GL Sciences (Tokyo, Japan) and Waters (MA, USA), respectively. Cyanidin and cyaniding 3-glucoside were purchased from TOKIWA PHYTOCHEMICAL (Chiba, Japan) and EXTRASYNTHÈSE (Cedex, France), respectively. Cyanidin 3, 5-diglucoside was obtained from Sigma–Aldrich (MO, USA). All other chemicals were of analytical grade and purchased from Wako Pure Chemicals (Osaka, Japan).

2.2. Assay of proteolytic activity

Enzyme activity was measured by fluorometrical determination (excitation, 380 nm; emission, 440 nm) of the liberation of AMC at 37 °C in a mixture containing 10 µl of 10 mM substrate, 100 µl of 0.5 M Tris–HCl buffer (pH 9.0), 5 µl of enzyme solution, and Milli Q water (18 mΩ) in a total volume of 1 ml. After incubation for 30 min, 2 ml of 0.2 M acetic acid was added to the mixture to terminate the reaction.

2.3. Identification of a DPP IV inhibitor

All fractionation steps were performed at room temperature unless otherwise specified. At each step, the inhibitory activity of DPP IV was measured in 50 mM Tris–HCl buffer (pH 9.0) using Gly-Pro-MCA as a substrate.

Step 1 Supel Sphere Carbon/NH₂ SPE chromatography

Aronia juice was applied at a flow rate of 5 ml/h to a Supel Sphere Carbon/NH₂ SPE Cartridge (bed volume: 6 ml) that had been




Fig. 1. Inhibition of DPP IV by aronia juice. A. DPP IV inhibitory activity by aronia juice was measured using a synthetic substrate, Gly-Pro-MCA. Values are means \pm S.E. $n = 4$ experiments. Statistically significant: *** $p < 0.001$. B. DPP IV inhibitory activities in fractions from Spelco column chromatography were measured using a synthetic substrate, Gly-Pro-MCA. Values are means \pm S.E. $n = 4$ experiments. Statistically significant: *** $p < 0.001$. Not significant: n.s.

previously equilibrated with 50 mM phosphate buffer (pH 7.0). After pass-through fractions had been collected, the column was washed extensively with ethanol and then eluted with a stepwise gradient of 50 mM phosphate buffer (pH 7.0) containing 2.0 M NaCl. Fractions with DPP IV inhibitory activity were subjected to the next step.

Step 2 Reversed-phase column chromatography

The sample solutions were subjected to reversed-phase HPLC on an InertSustain C18 column (4.6 \times 150 mm) using a 0–100% acetonitrile/0.1% TFA gradient at a flow rate of 1.0 ml/min. Each peak was evaporated, and peaks containing DPP IV inhibitory activity were subjected to the next step.

Step 3 LC–MS/MS analysis

The sample solutions were subjected to an ACQUITY UPLC M-Class HSS T3 column (75 μ m \times 150 mm) using an ACQUITY UPLC M-Class system at a flow rate of 5 μ l/min. MS/MS experiments were performed using a Xevo G2 QToF (Waters, MA, USA) with an ESI source. MassLynx v4.1 software was used for instrument control and data acquisition. The capillary temperature was 120 °C, and the capillary voltage was 3 kV. Mass spectra were recorded between m/z 100 and 1000 in the positive ion mode.

2.4. Statistical analysis

Data are expressed as means \pm S.E. Statistical analyses were performed using analysis of variance (one-way ANOVA) followed




Fig. 2. Separation of the DPP IV inhibitory fraction through column chromatography. A. Separation of a DPP IV inhibitor using RP-HPLC. Four fractions were obtained. B. Enzyme activities the fractions were measured. Fraction number 2 had inhibitory activity against DPP IV, and its visible colour was shown to be red. Values are means \pm S.E. $n = 4$ experiments. Statistically significant: *** $p < 0.001$. Not significant: n.s. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

by unpaired Student's *t*-test. For comparison of multiple samples, the Tukey–Kramer test was used.

3. Results

3.1. DPP IV inhibitory activity in aronia juice

To examine DPP IV inhibitory effect in aronia juice, DPP IV activity against a synthetic substrate, Gly-Pro-MCA, was examined. As shown Fig. 1A, DPP IV inhibitory activity was observed in aronia juice and the rate of reduction in DPP IV activity was about 27% of that by a vehicle control.

3.2. Isolation of a DPP IV inhibitor from aronia juice

To isolate a DPP IV inhibitor(s) from aronia juice, aronia juice was fractionated by column chromatography. As shown in Fig. 1B, DPP IV inhibitory activity was observed in the eluted fraction but not in the pass-through fraction from the Supel Sphere Carbon/NH₂ SPE Cartridge, and the rate of reduction in DPP IV activity was about 28% of that by a vehicle control. Furthermore, fractions with DPP IV inhibitory activity were fractionated by reversed-phase column

chromatography, and four fractions were obtained (Fig. 2A). As shown in Fig. 2B, DPP IV inhibitory activity was observed in fraction 2 and its rate of reduction in DPP IV activity was about 81% of that by the control.

3.3. Identification of a DPP IV inhibitor in aronia juice

To identify a DPP IV inhibitor(s), the solution with DPP IV inhibitory activity was subjected to UPLC-Xevo G2 QToF. As shown in Fig. 3A, the molecular mass of the main peak was 635.74, and 451.56 and 289.38 *m/z* fragment peaks were also obtained from MS/MS peaks of the main peak. Since peaks of 451.56 and 289.38 *m/z* were identified to be cyanidin 3-glucoside and cyanidin, respectively, 635.74 and 613.74 *m/z* peaks were identified to be cyanidin 3, 5-diglucoside (Fig. 3B) according to the literature [11–13].

3.4. Measurement of IC₅₀ of cyanidin 3, 5-diglucoside

To examine whether DPP IV enzyme activity is inhibited by cyanidin 3, 5-diglucoside, a DPP IV activity assay was carried out using synthetic Gly-Pro-MCA as a substrate. As shown in Fig. 4 DPP IV was inhibited by 0.5 μM cyanidin 3, 5-diglucoside but not by




Fig. 3. Identification of a DPP IV inhibitor. A. LC–MS spectrum of fractions with DPP IV inhibitory activity. B. MS/MS spectrum of main peaks. Cyanidin 3-glucoside and cyanidin were detected in fragment peaks, and the main peak was identified to be cyanidin 3, 5-diglucoside.




Fig. 4. Inhibition of DPP IV by cyanidin, cyanidin 3-glucoside and cyanidin 3, 5-diglucoside. Inhibitory activities of cyanidin, cyanidin 3-glucoside and cyanidin 3, 5-diglucoside against DPP IV were measured. DPP IV activity was inhibited by about 25% by cyanidin 3, 5-diglucoside but not by cyanidin or cyanidin 3-glucoside. Values are means \pm S.E. $n = 4$ experiments. Statistically significant: ** $p < 0.01$.

cyanidin or cyanidin 3-glucoside. The IC₅₀ value of cyanidin 3, 5-diglucoside was estimated to be 5.5 μ M.

4. Discussion

Although aronia juice has been shown to have a beneficial effect on plasma glucose level, its mechanism is unknown. Both GLP-1 and GIP are rapidly inactivated by DPP IV [14]. We found that aronia juice has DPP IV inhibitory activity. DPP IV inhibitors have been found in foods and food protein hydrolysates. DPP IV is inhibited by *Pterocarpus marsupium* Roxb. (Leguminosae), *Agonia cretica* L. (Zygophyllaceae) and *Hedera nepalensis* K. Koch (Araliaceae) [15,16]. In this study, a new DPP IV inhibitor, cyanidin 3, 5-diglucoside, was identified. Cyanidin 3, 5-diglucoside in aronia juice fraction was found as the main component to act as a DPP IV inhibitor. It has been reported that phenolic compounds such as cyanidin, cyaniding-3-glucoside, malvidin, luteolin, apigenin, quercetin, kaempferol, hesperetin, naringenin, eriocitrin, genistein, resveratrol, gallic acid and caffeic acid are DPP IV inhibitors in berries and citrus fruit [17]. In food protein hydrolysates, DPP IV inhibitors have been reported to be derivative peptides from atlantic salmon skin, tuna cooking juice, Japanese rice bran, gouda cheese and milk protein [18]. Previous studies have also shown that aronia juice contains anthocyanin glycosides including cyanidin 3-galactoside, cyanidin 3-arabinoside, cyanidin 3-glucoside and cyanidin 3-xyloside [19–24]. Furthermore, cyanidin and cyanidin 3-glucoside have been reported to be DPP IV inhibitors [17]. We found that DPP IV activity was inhibited more strongly by cyanidin 3, 5-diglucoside than by cyanidin and cyanidin 3-glucoside, which have been reported to be DPP IV inhibitors. Our results and results of previous studies suggest that cyanidin 3, 5-diglucoside is a new inhibitor present in aronia juice.

Competing interests

The authors have declared that no competing interests exist.

Acknowledgements

This work was supported by the Scientific Research Fund from Nakagaki Consulting Engineer.

Transparency document

Transparency document related to this article can be found online at <http://dx.doi.org/10.1016/j.bbrc.2015.08.031>.

References

- [1] E.S. Kulling, M.H. Rawel, Chokeberry (*Aronia melanocarpa*) – a review on the characteristic components and potential health effects, *Planta Med.* 74 (2008) 1625–1634.
- [2] M. Badescu, O. Badulescu, L. Badescu, M. Ciocoiu, Effects of *Sambucus nigra* and *Aronia melanocarpa* extracts on immune system disorders within diabetes mellitus, *Pharm. Biol.* 53 (2015) 533–539.
- [3] S. Valcheva-Kuzmanova, K. Kuzmanov, S. Tancheva, A. Belcheva, Hypoglycemic and hypolipidemic effects of *Aronia melanocarpa* fruit juice in streptozotocin-induced diabetic rats, *Methods Find. Exp. Clin. Pharmacol.* 29 (2007) 101–105.
- [4] I. Ohkubo, K. Huang, Y. Ochiai, M. Takagaki, K. Kani, Dipeptidyl peptidase IV from porcine seminal plasma: purification, characterization, and N-terminal amino acid sequence, *J. Biochem.* 116 (1994) 1182–1186.
- [5] T.J. Kieffer, C.H.S. McIntosh, R.A. Pederson, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, *Endocrinology* 136 (1995) 3585–3596.
- [6] L. Pridal, C.F. Deacon, O. Kirk, J.V. Christensen, R.D. Carr, J.J. Holst, Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36) amide in dogs and is degraded more quickly in vitro by dog plasma, *Eur. J. Drug Metab. Pharmacokinet.* 21 (1996) 51–59.
- [7] R. Mentlein, Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides, *Regul. Pept.* 85 (1999) 9–24.
- [8] L.L. Baggio, D.J. Drucker, Biology of incretins: GLP-1 and GIP, *Gastroenterology* 132 (2007) 2131–2157.
- [9] J. Zhong, Q. Gong, A. Goud, S. Srinivasamaharaj, S. Rajagopalan, Recent advances in dipeptidyl-peptidase-4 inhibition therapy: lessons from the bench and clinical trials, *J. Diabetes Res.* 2015 (2015) 606031.
- [10] J.L. Rios, F. Francini, G.R. Schinella, Natural products for the treatment of type 2 diabetes mellitus, *Planta Med.* 1 (2015).
- [11] K. Schütz, M. Persike, R. Carle, A. Schieber, Characterization and quantification of anthocyanins in selected artichoke (*Cynara scolymus* L.) cultivars by HPLC-DAD-ESI-MSn, *Anal. Bioanal. Chem.* 384 (2006) 1511–1517.
- [12] J.Y. Choi, S.J. Lee, S.J. Lee, S. Park, J.H. Lee, J.H. Shim, A.M. Abd El-Aty, J.S. Jin, E.D. Jeong, W.S. Lee, S.C. Shin, Analysis and tentative structure elucidation of new anthocyanins in fruit peel of *Vitis coignetiae* Pulliat (meoru) using LC-MS/MS: contribution to the overall antioxidant activity, *J. Sep. Sci.* 33 (2010) 1192–1197.
- [13] J.S. Barnes, K.A. Schug, Structural characterization of cyaniding-3,5-diglucoside and pelargonidin-3,5-diglucoside anthocyanins: multi-dimensional fragmentation pathways using high performance liquid chromatography-electrospray ionization-ion trap-time of flight mass spectrometry, *Int. J. Mass Spectrom.* 308 (2011) 71–80.
- [14] S. Cernea, I. Raz, Therapy in the early stage: incretins, *Diabetes Care* 34 (2011) S264–S271.
- [15] J. Kosaraju, A. Dubala, S. Chinni, R.B. Khatwal, M.N. Satish Kumar, D. Basavan, A molecular connection of *Pterocarpus marsupium*, *Eugenia jambolana* and *Gymnema sylvestre* with dipeptidyl peptidase-4 in the treatment of diabetes, *Pharm. Biol.* 52 (2014) 268–271.
- [16] S. Saleem, L. Jafri, I.U. Haq, L. Chee Chang, D. Calderwood, B.D. Green, B. Mirza, Plants *Fagonia cretica* L. and *Hedera nepalensis* K. Koch contain natural compounds with potent dipeptidyl peptidase-4 (DPP-4) inhibitory activity, *J. Ethnopharmacol.* 1156 (2014) 26–36.
- [17] J. Fan, M.H. Johnson, M.A. Lila, G. Yousef, E.G. de Mejia, Berry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: implications in diabetes management, *Evid. Based Complement. Altern. Med.* 2013 (2013) 479505.
- [18] R. Fontoura, D.J. Daroit, A.P. Correa, S.M. Meira, M. Mosquera, A. Brandelli, Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes, *Proc. Nutr. Soc.* 73 (2014) 34–46.
- [19] W. Zheng, S.Y. Wang, Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries, *J. Agric. Food Chem.* 51 (2003) 502–509.
- [20] X. Wu, L. Gu, R.L. Prior, S. McKay, Characterization of anthocyanins and proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their antioxidant capacity, *J. Agric. Food Chem.* 52 (2004) 7846–7856.
- [21] N. Ryszawa, A. Kawczyńska-Drózd, J. Pryjma, M. Czesnikiewicz-Guzik, T. Adamek-Guzik, M. Naruszewicz, R. Korbut, T.J. Guzik, Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis, *J. Physiol. Pharmacol.* 57 (2006) 611–626.
- [22] A. Jurgónski, J. Juśkiewicz, Z. Zduńczyk, Ingestion of black chokeberry fruit extract leads to intestinal and systemic changes in a rat model of prediabetes and hyperlipidemia, *Plant Foods Hum. Nutr.* 63 (2008) 176–182.
- [23] M. Bräunlich, R. Slimestad, H. Wangensteen, C. Brede, K.E. Malterud, H. Barsett, Extracts, anthocyanins and procyanidins from *Aronia melanocarpa* as radical scavengers and enzyme inhibitors, *Nutrients* 5 (2013) 663–678.
- [24] D. Rugină, Z. Diaconeasa, C. Coman, A. Bunea, C. Socaciu, A. Pintea, Chokeberry anthocyanin extract as pancreatic β -cell protectors in two models of induced oxidative stress, *Oxid. Med. Cell Longev.* 2015 (2015) 429075.